Knockdown of TONSL by siRNA treatment in patient cells from SPONASTRIME dysplasia, a rare weak bone disease caused by hypomorphic mutation of TONSL, reduces RAD51 foci upon CPT treatment, revealing its essential role in RAD51’s ability to load to DNA damage sites by interacting with RPA [202,203]. Here, TONSL is linked to dysplasia.